Company Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization.
NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
| Country | United States |
| Founded | 2001 |
| IPO Date | Nov 2, 1999 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,200 |
| CEO | Anthony Zook |
Contact Details
Address: 9490 NeoGenomics Way Fort Myers, Florida 33912 United States | |
| Phone | 239 768 0600 |
| Website | neogenomics.com |
Stock Details
| Ticker Symbol | NEO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001077183 |
| CUSIP Number | 64049M209 |
| ISIN Number | US64049M2098 |
| Employer ID | 74-2897368 |
| SIC Code | 8734 |
Key Executives
| Name | Position |
|---|---|
| Anthony P. Zook | Chief Executive Officer and Director |
| Warren Stone | President and Chief Operating Officer |
| Jeffrey S. Sherman M.B.A. | Chief Financial Officer |
| Alicia C. Olivo | Executive Vice President of Business Development, General Counsel and Corporate Secretary |
| Gregory D. Aunan | Senior Vice President and Chief Accounting Officer |
| Kendra Sweeney | Vice President of Investor Relations and Communications |
| Hutan Hashemi J.D. | Chief Compliance Officer |
| Gary Passman | Chief People and Culture Officer |
| Kareem M. Saad | Head of Strategy, Business Development and Transformation |
| Dr. Andrew A. Lukowiak Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | ARS | Filing |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K/A | [Amend] Current report |
| Mar 19, 2025 | 8-K/A | [Amend] Current report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 18, 2025 | SCHEDULE 13G | Filing |
| Feb 18, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | 8-K | Current Report |